Discovery of new drug platforms

Additionally, we are discovering bispecific small molecules (BSM) and inhibitor-drug-conjugates (IDC) that are small molecules acting like bispecific antibodies, and antibody-drug-conjugates (ADC), respectively. Lead compounds have been discovered, and currently, optimizations are in progress. One of example for BSM is the above 3rdgeneration cancer immunotherapy.